Last reviewed 2026-04-20 · How we verify

Vocabria (CABOTEGRAVIR)

Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate.

Vocabria (cabotegravir) is a small molecule Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor developed by Viiv Healthcare. It was FDA approved in 2021 for the treatment of Human Immunodeficiency Virus I infection. Vocabria works by inhibiting the integrase enzyme, which is essential for the replication of the virus. It is a patented medication with no generic manufacturers available. Key safety considerations include the potential for adverse reactions such as injection site reactions and allergic reactions.

At a glance

Mechanism of action

Cabotegravir is an HIV-1 antiretroviral drug [see Microbiology (12.4)].

Approved indications

• Human immunodeficiency virus I infection

Common side effects

• Diarrhea
• Nausea
• Dizziness
• Headache
• Fatigue
• Abnormal dreams
• Upper respiratory tract infection
• Somnolence
• Abdominal pain
• Vomiting
• Decreased appetite
• Pruritus

Key clinical trials

• CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2,PHASE3)
• Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs (PHASE4)
• Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (PHASE2)
• Antiviral Long Acting Drugs Landing in People Living With HIV (NA)
• A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.